Published in Blood on November 16, 2004
Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis. Clin Microbiol Rev (2009) 3.10
Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production. Eukaryot Cell (2006) 1.92
Aspergillus fumigatus: principles of pathogenesis and host defense. Eukaryot Cell (2007) 1.74
Gliotoxin is a virulence factor of Aspergillus fumigatus: gliP deletion attenuates virulence in mice immunosuppressed with hydrocortisone. Eukaryot Cell (2007) 1.69
GliZ, a transcriptional regulator of gliotoxin biosynthesis, contributes to Aspergillus fumigatus virulence. Infect Immun (2006) 1.61
Role of laeA in the Regulation of alb1, gliP, Conidial Morphology, and Virulence in Aspergillus fumigatus. Eukaryot Cell (2007) 1.41
A nonredundant role for plasmacytoid dendritic cells in host defense against the human fungal pathogen Aspergillus fumigatus. Cell Host Microbe (2011) 1.41
Neosartorya udagawae (Aspergillus udagawae), an emerging agent of aspergillosis: how different is it from Aspergillus fumigatus? J Clin Microbiol (2009) 1.23
Distinct responses of human monocyte subsets to Aspergillus fumigatus conidia. J Immunol (2009) 1.18
Frequency and species distribution of gliotoxin-producing Aspergillus isolates recovered from patients at a tertiary-care cancer center. J Clin Microbiol (2005) 1.17
What do we know about the role of gliotoxin in the pathobiology of Aspergillus fumigatus? Med Mycol (2008) 1.16
Healthy human T-Cell Responses to Aspergillus fumigatus antigens. PLoS One (2010) 1.14
Human dendritic cells following Aspergillus fumigatus infection express the CCR7 receptor and a differential pattern of interleukin-12 (IL-12), IL-23, and IL-27 cytokines, which lead to a Th1 response. Infect Immun (2006) 1.02
VeA regulates conidiation, gliotoxin production, and protease activity in the opportunistic human pathogen Aspergillus fumigatus. Eukaryot Cell (2012) 0.94
The temporal dynamics of differential gene expression in Aspergillus fumigatus interacting with human immature dendritic cells in vitro. PLoS One (2011) 0.93
Toward awakening cryptic secondary metabolite gene clusters in filamentous fungi. Methods Enzymol (2012) 0.90
Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production in Aspergillus fumigatus. PeerJ (2013) 0.90
The fumagillin gene cluster, an example of hundreds of genes under veA control in Aspergillus fumigatus. PLoS One (2013) 0.89
RsmA regulates Aspergillus fumigatus gliotoxin cluster metabolites including cyclo(L-Phe-L-Ser), a potential new diagnostic marker for invasive aspergillosis. PLoS One (2013) 0.88
Natural killer cells and antifungal host response. Clin Vaccine Immunol (2013) 0.88
Interference of Aspergillus fumigatus with the immune response. Semin Immunopathol (2014) 0.87
The growing promise of Toll-deficient Drosophila melanogaster as a model for studying Aspergillus pathogenesis and treatment. Virulence (2010) 0.87
Spatial and temporal control of fungal natural product synthesis. Nat Prod Rep (2014) 0.85
Immune responses of human immature dendritic cells can be modulated by the recombinant Aspergillus fumigatus antigen Aspf1. Clin Vaccine Immunol (2009) 0.82
Aspergillosis and stem cell transplantation: An overview of experimental pathogenesis studies. Virulence (2016) 0.82
Genomewide screening for genes associated with gliotoxin resistance and sensitivity in Saccharomyces cerevisiae. Antimicrob Agents Chemother (2008) 0.82
Extrolites of Aspergillus fumigatus and Other Pathogenic Species in Aspergillus Section Fumigati. Front Microbiol (2016) 0.81
The Master Transcription Factor mtfA Governs Aflatoxin Production, Morphological Development and Pathogenicity in the Fungus Aspergillus flavus. Toxins (Basel) (2016) 0.81
Fungi infecting plants and animals: killers, non-killers, and cell death. PLoS Pathog (2013) 0.79
Anti-Immune Strategies of Pathogenic Fungi. Front Cell Infect Microbiol (2016) 0.79
The mtfA transcription factor gene controls morphogenesis, gliotoxin production, and virulence in the opportunistic human pathogen Aspergillus fumigatus. Eukaryot Cell (2014) 0.78
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. Biol Blood Marrow Transplant (2016) 0.78
Slaughterhouses Fungal Burden Assessment: A Contribution for the Pursuit of a Better Assessment Strategy. Int J Environ Res Public Health (2016) 0.78
Adoptive immunity mediated by HLA-A*0201 restricted Asp f16 peptides-specific CD8+ T cells against Aspergillus fumigatus infection. Eur J Clin Microbiol Infect Dis (2012) 0.77
Microbial egress: a hitchhiker's guide to freedom. PLoS Pathog (2014) 0.77
Gliotoxin Suppresses Macrophage Immune Function by Subverting Phosphatidylinositol 3,4,5-Trisphosphate Homeostasis. MBio (2016) 0.77
Severe Sequelae to Mold-Related Illness as Demonstrated in Two Finnish Cohorts. Front Immunol (2017) 0.75
Antifungal and antihepatotoxic effects of sepia ink extract against oxidative stress as a risk factor of invasive pulmonary aspergillosis in neutropenic mice. Afr J Tradit Complement Altern Med (2014) 0.75
Sinonasal tumor in 3 dogs after successful topical treatment for frontal sinus aspergillosis. Can Vet J (2009) 0.75
Transcriptional Control of Drug Resistance, Virulence and Immune System Evasion in Pathogenic Fungi: A Cross-Species Comparison. Front Cell Infect Microbiol (2016) 0.75
Airway centered invasive pulmonary aspergillosis in an immunocompetent patient: case report and literature review. J Thorac Dis (2016) 0.75
Gliotoxin Inhibits Proliferation and Induces Apoptosis in Colorectal Cancer Cells. Mar Drugs (2015) 0.75
Regulation of Secondary Metabolism by the Velvet Complex Is Temperature-Responsive in Aspergillus. G3 (Bethesda) (2016) 0.75
A new approach to assess occupational exposure to airborne fungal contamination and mycotoxins of forklift drivers in waste sorting facilities. Mycotoxin Res (2017) 0.75
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis (2005) 13.97
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis (2006) 3.57
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother (2011) 3.04
Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis (2004) 2.81
Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis (2008) 2.65
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis (2006) 2.45
Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica (2006) 2.41
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis (2011) 2.17
Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood (2007) 2.16
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Pathogenesis of mucormycosis. Clin Infect Dis (2012) 2.14
Glucocorticoids and invasive fungal infections. Lancet (2003) 2.11
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother (2008) 2.06
Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis (2005) 2.06
Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis (2012) 1.96
Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol (2003) 1.96
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 1.94
Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol (2012) 1.93
Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect (2011) 1.90
Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis (2008) 1.88
Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev (2011) 1.82
Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Antimicrob Agents Chemother (2007) 1.76
Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother (2005) 1.75
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis (2004) 1.74
Diagnosis of invasive mold infection by real-time quantitative PCR. Am J Clin Pathol (2003) 1.73
Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer (2009) 1.69
Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.68
Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Infect (2010) 1.67
Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.67
Breast implant infections: is cefazolin enough? Plast Reconstr Surg (2010) 1.67
Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J Infect Dis (2008) 1.64
Tuberculosis: a benign impostor. AJR Am J Roentgenol (2010) 1.62
Escherichia coli Pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis (2010) 1.60
The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med (2002) 1.60
Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis (2010) 1.58
Pulmonary mucormycosis. Semin Respir Crit Care Med (2011) 1.58
Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis (2008) 1.57
Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc (2008) 1.56
Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis (2010) 1.55
Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A (2008) 1.54
Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) (2003) 1.51
MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. Blood (2013) 1.50
The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis (2011) 1.49
Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. J Infect Dis (2013) 1.49
Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2002) 1.47
Aminopeptidase N inhibitors and SARS. Lancet (2003) 1.47
Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis (2005) 1.47
Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis (2006) 1.46
Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis (2006) 1.46
Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis (2012) 1.45
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol (2012) 1.44
Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis (2009) 1.44
Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis (2014) 1.42
Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood (2004) 1.42
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood (2002) 1.39
Detection of gliotoxin in experimental and human aspergillosis. Infect Immun (2005) 1.38
Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther (2013) 1.36
Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrob Agents Chemother (2002) 1.36
Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis (2011) 1.34
Isogenic auxotrophic mutant strains in the Aspergillus fumigatus genome reference strain AF293. Arch Microbiol (2004) 1.34
Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis (2009) 1.33
Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol (2008) 1.33
Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect (2010) 1.32
Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis (2006) 1.31
Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood (2009) 1.28
Generation of IL-23 producing dendritic cells (DCs) by airborne fungi regulates fungal pathogenicity via the induction of T(H)-17 responses. PLoS One (2010) 1.25
Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine. J Infect (2002) 1.23
Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011). Clin Infect Dis (2012) 1.22
Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2006) 1.21
Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol (2010) 1.21
Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer (2004) 1.20
Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood (2004) 1.18
Epidemiology and treatment of mucormycosis. Future Microbiol (2013) 1.18
Frequency and species distribution of gliotoxin-producing Aspergillus isolates recovered from patients at a tertiary-care cancer center. J Clin Microbiol (2005) 1.17
Fusobacterial brain abscess: a review of five cases and an analysis of possible pathogenesis. J Neurosurg (2003) 1.16
Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses (2013) 1.15
Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis (2005) 1.13
Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother (2006) 1.13
Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units. Br J Haematol (2002) 1.13
Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther (2013) 1.13
Risk factors for mortality in patients with mucormycosis. Med Mycol (2012) 1.13
Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother (2008) 1.12
Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res (2012) 1.12
Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother (2012) 1.11
Mold infections of the central nervous system. N Engl J Med (2014) 1.11
A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. J Infect (2009) 1.10